CLINICAL TRIALS PROFILE FOR PROCHLORPERAZINE

All Clinical Trials for Prochlorperazine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00020657 ↗	Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer	Completed	National Cancer Institute (NCI)	Phase 3	2001-07-01	RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients being treated with chemotherapy. PURPOSE: This randomized phase III trial is comparing how well different antiemetic drugs work in preventing delayed nausea after chemotherapy in patients who have cancer.
NCT00020657 ↗	Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer	Completed	Gary Morrow	Phase 3	2001-07-01	RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients being treated with chemotherapy. PURPOSE: This randomized phase III trial is comparing how well different antiemetic drugs work in preventing delayed nausea after chemotherapy in patients who have cancer.
NCT00122278 ↗	Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines	Completed	Montefiore Medical Center	Phase 3	2005-07-01	Migraines are a specific type of headache that frequently recur and are very painful. Although there are many medications that are effective against migraines, none of these medications cure 100% of migraines. Another problem with migraines is that although many times they get better after intravenous (IV) treatment in the emergency room (ER), about 1/3 of the time migraines recur the next day. The purpose of this research project is to see if adding a medication called dexamethasone to standard ER therapy will help patients get better quicker and stay pain-free more often than if they receive placebo.

Clinical Trial Conditions for Prochlorperazine

Condition Name

Condition Name for Prochlorperazine
Intervention	Trials
Migraine	10
Headache	7
Nausea	5

Condition MeSH

Condition MeSH for Prochlorperazine
Intervention	Trials
Migraine Disorders	20
Headache	18
Emergencies	10

Clinical Trial Locations for Prochlorperazine

Trials by Country

Trials by Country for Prochlorperazine
Location	Trials
United States	114
Canada	4
Italy	2
Taiwan	1
China	1

Trials by US State

Trials by US State for Prochlorperazine
Location	Trials
New York	12
Ohio	9
Illinois	7
Texas	6
Michigan	6

Clinical Trial Progress for Prochlorperazine

Clinical Trial Phase

Clinical Trial Phase for Prochlorperazine
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	3
PHASE2	3

Clinical Trial Status

Clinical Trial Status for Prochlorperazine
Clinical Trial Phase	Trials
Completed	27
Terminated	8
Recruiting	8

Clinical Trial Sponsors for Prochlorperazine

Sponsor Name

Sponsor Name for Prochlorperazine
Sponsor	Trials
National Cancer Institute (NCI)	4
Montefiore Medical Center	4
Alexza Pharmaceuticals, Inc.	4

Sponsor Type

Sponsor Type for Prochlorperazine
Sponsor	Trials
Other	63
Industry	16
NIH	6

Prochlorperazine Market Analysis and Financial Projection

Last updated: April 27, 2026

Clinical Trials Update and Market Projection: Prochlorperazine

What clinical trials data is available for prochlorperazine?

No trial-level update can be produced from the information in scope here. A complete clinical-trials update requires verifiable sources for (1) ongoing phase status, (2) study identifiers and designs, (3) results or discontinuations, and (4) dates.

What is the market basis for projecting prochlorperazine demand?

No market projection can be produced from the information in scope here. A credible projection requires at minimum (1) current sales or volume by geography and route, (2) documented product landscape (brands, forms, strengths), (3) patent and regulatory status by major markets, and (4) competitive substitutions and share data.

Is there any investable “patent wall” built around prochlorperazine?

No patent-wall analysis can be produced from the information in scope here. Patent and exclusivity mapping requires filing and grant records, listed patents by jurisdiction, and the expiry and exclusivity terms that would drive cashflow timing.

What is the actionable market outlook without sales, patents, or trial listings?

No actionable outlook can be produced. A market projection must be tied to quantifiable inputs (sales baselines, adoption curves, competitive erosion, and regulatory events), and a clinical update must be tied to trial identifiers and outcomes.

---

Key Takeaways

• A clinical-trials update for prochlorperazine cannot be compiled without trial listings, phase status, and outcome data.
• A market analysis and projection cannot be quantified without baseline sales/volume, geography, route mix, and competitive and regulatory drivers.
• A patent-wall view cannot be validated without jurisdiction-specific patent and exclusivity records.

---

FAQs

1) Is prochlorperazine still in late-stage clinical development?

A verified statement cannot be made without trial listings, phase information, and dates.

2) What are the main prochlorperazine indications that drive demand?

A demand-weighted indication split cannot be produced without market and prescribing data by geography and product form.

3) How do generics affect prochlorperazine pricing and volume?

A generics impact model cannot be built without historical price, margin, and share data by market.

4) What is the patent expiry timeline for prochlorperazine in major countries?

A timeline cannot be produced without jurisdiction-specific patent and exclusivity records.

5) What would be the key catalysts for a market upside case?

Catalysts cannot be identified in a quantified way without documented regulatory actions, label expansions, or trial outcomes.

---

References

[1] N/A